



# Aurinia™

## COMPANY OVERVIEW

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs. The Company's head office is in Victoria, British Columbia and its U.S. commercial hub is in Rockville, Maryland. The Company focuses its development efforts globally.

## RECENT NEWS

### Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences

Sep 15 2021, 1:11 PM EDT

## STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

## INVESTOR RELATIONS

Dana Lynch  
Director, Corporate Communications  
[dlynch@auriniapharma.com](mailto:dlynch@auriniapharma.com)  
[IR@auriniapharma.com](mailto:IR@auriniapharma.com)

## MANAGEMENT TEAM

**Peter Greenleaf**  
Chief Executive Officer, Director

**Max Colao**  
Chief Commercial Officer

**Max Donley, MBA**  
Executive Vice President, Operations and Strategy

**Robert Huizinga, Ph.D., R.N., CNeph(C)**  
Executive Vice President of Research

**Michael Martin**  
Chief Business Officer

**Joe Miller**  
Chief Financial Officer

**Stephen Robertson**  
Executive Vice President, General Counsel,  
Corporate Secretary & Chief Compliance  
Officer

**Neil Solomons, M.D.**  
Chief Medical Officer

## AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street  
Victoria, BC V8Z 7X8  
Canada

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.